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Background
Hybridoma technology was established in the 2nd half
of the 20th century and in the view of current protein
production it might seem old-fashioned. Despite, it is
commonly used to produce monoclonal antibodies
(mAbs) for R & D, clinical diagnostics or medical appli-
cations and the demand for mAbs produced by hybrido-
mas is still high. However, compared to CHO, only a
few serum-free hybridoma media are available and even
less suppliers for chemically defined products are on the
market. In this work, a new chemically defined medium
and feed were developed to bring hybridoma processes
to the next level and to target the existing gap in the
market.
Materials and methods
HybriMACS CD medium was developed using various
research and production hybridoma cell lines from Biele-
feld University (e.g. MF20, 187.1, HB8209) and industrial
partners. HybriMACS CD medium was supplemented
with 8 mM L-Glutamine for routine cultivation, batch
and perfusion processes. For optimal performance of
MF20 hybridoma cells (DSHB at the University of Iowa)
the HybriMACS CD medium was supplemented with
insulin (4 mg/L) or IGF (0.04 mg/L).
All cultivations were carried out using standard condi-
tions. Briefly, precultures and batch cultivations were
performed in 125 mL and 250 mL Erlenmeyer flasks.
Incubator conditions were set to 37 °C, 5% CO2 and a
relative humidity of 80%. For bioreactor cultivations
closed-loop controlled 2 L benchtop systems were used
with parameters set to 37 °C, 40% DO and pH 7.1 +/-
0.05. Automated viable cell counting was performed
using a Cedex (Innovatis). Monoclonal antibody (mAb)
concentrations were determined with Protein A HPLC
or ELISA (MF20 cell line).
Results
Hybridoma cell growth in HybriMACS CD medium was
compared to 12 competitor products in the time course
of several passages and a final batch cultivation. For a
mouse-mouse hybridoma cell line, maximum viable cell
density (vcd) in HybriMACS CD was highest and for a
rat-mouse hybridoma cell line second-highest compared
to growth in the 12 competitor media, as shown in
Figure 1 (A).
Easy adaption from serum-containing medium was
verified by direct thawing of five different hybridoma
cell lines in HybriMACS CD (Figure 1 B). Furthermore,
long-term stable growth of a hybridoma cell line in
HybriMACS CD was also confirmed in cultivations for
more than 80 days.
The majority of tested cell lines reached a maximum
cell density above 2.5 to 5.0 × 106 cells/mL in uncon-
trolled and controlled batch processes using Hybri-
MACS CD. For uncontrolled fed batch cultivations 1.0
× 107 cells/mL were observed as maximum viable cell
density, while controlled fed batch processes reached
values above 1.5 × 107 cells/mL. The final antibody titer
was increased at least by a factor of 5 in uncontrolled
fed batches and up to 10 times in controlled fed batch
cultivations using HybriMACS Feed Supplement.
Exemplary results of controlled as well as uncontrolled
batch and fed batch cultivations are shown in Table 1.
Conclusions
HybriMACS CD is a chemically-defined, protein-free
medium composition with no need for growth hormone
supplementation. The specially designed formulation
supports direct adaption of serum-dependent hybridoma
cells, even when starting from a serum-containing cell
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bank. In addition, the developed medium formulation
enables stable long-term growth of hybridoma cell lines,
supporting an unrestricted utilization in diverse pro-
cesses. HybriMACS CD is suitable for bioreactor batch
and perfusion processes reaching high cell densities and
commonly accepted amounts of antibody. A specially
tailored HybriMACS Feed Supplement increased final
antibody titer at least by a factor of 5 to 10 for all tested
hybridoma cell lines. This improvement can be further
increased by customization of the generic feed regime,
while maintaining suitable glucose and glutamine
concentrations.
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Figure 1 (A) Comparison of two different hybridoma cell lines in HybriMACS CD and 12 competitor media. (B) Growth behaviour of five
serum-dependent hybridoma cell lines in HybriMACS CD directly after thawing.
Table 1 Exemplary data of batch and fed batch




















Values represent mean from two biological replicates.
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